09 January 2026 : Clinical Research
Baseline Tumor Biology Predicts Survival After Recurrence in Gastric Cancer: Impact of LVI, PNI, and HER2 Status
Gözde Ağdaş
ABCDE 1*, Mehmet Salim Demir AF 1
DOI: 10.12659/MSM.951829
Med Sci Monit 2026; 32:e951829
Table 1 Baseline demographic and clinicopathological characteristics of the patients.
| Min–Max | Median | Mean±SD/n-% | |||
|---|---|---|---|---|---|
| Age | 36.1–81.9 | 62.9 | 62.3±8.4 | ||
| Sex | 1 | 27 | 38.6% | ||
| 2 | 43 | 61.4% | |||
| Her2 IHC | 0 | 43 | 61.4% | ||
| I | 6 | 8.6% | |||
| II | 5 | 7.1% | |||
| III | 10 | 14.3% | |||
| Not available | 6 | 8.6% | |||
| Lauren | Diffuse | 18 | 25.7% | ||
| Intestinal | 40 | 57.1% | |||
| Not available | 12 | 17.1% | |||
| Grade | I | 4 | 5.7% | ||
| II | 33 | 47.1% | |||
| III | 29 | 41.4% | |||
| Not available | 4 | 5.7% | |||
| Neoadjuvant CT | 23 | 32.9% | |||
| Surgery type | Subtotal gastectomy | 8 | 11.4% | ||
| Total gastrectomy | 62 | 88.6% | |||
| pTNM stage | I | 5 | 7.1% | ||
| II | 11 | 15.7% | |||
| III | 54 | 77.1% | |||
| cT | I | 12 | 17.1% | ||
| II | 10 | 14.3% | |||
| III | 33 | 47.1% | |||
| IV | 15 | 21.4% | |||
| cN | Negative | 18 | 25.7% | ||
| Positive | 52 | 74.3% | |||
| cTNM stage | I | 15 | 21.4% | ||
| II | 15 | 21.4% | |||
| III | 40 | 57.1% | |||